Dose Titration Algorithm Tuning
About
Bibliography
DTAT
Categories
All
(26)
dialogues
(1)
explainers
(5)
journal
(3)
longer-videos
(1)
short-videos
(3)
tweetorials
(6)
under-review
(1)
unfit_to_print
(3)
How large must a dose-optimization trial be?
explainers
This is a lay explanation for my paper accepted for publication in a
CPT: Pharmacometrics & Systems Pharmacology
special themed issue on Dose Optimization in Oncology
Sep 29, 2023
Project Optimus as Pseudoscience
journal
I analyze FDA Oncology’s Project Optimus using tools from scholarly studies of pseudoscience
Sep 13, 2023
Complete Path Enumeration (CPE)
tweetorials
This demonstrates the feasibility of a programme I’ve set forth, for the ‘exact’ simulation of ANY dose-escalation design.
Influenced by
@MarkusTriska
‘s exacting perspective…
Jul 9, 2021
What Were They Thinking?
tweetorials
This thread introduces a Dec 2020 paper I posted on arXiv, containing several important elements including the advent of what I have since termed complete path enumeration (C…
Jul 9, 2021
Debut of R package ‘precautionary’
tweetorials
This thread marked the debut of R package
precautionary
. The historical origins documented here remain of interest, despite major (and ongoing, mid-2021) improvements that…
Jul 9, 2021
Notes on therapeutic index in oncology dose finding
tweetorials
Announcing an important update to the EscRisk app, with provisional efforts to trace the
therapeutic index
idea within the oncology dose-finding literature…
Jul 9, 2021
An Article of Impeachment
tweetorials
This tweetorial explains a Dec 2019 preprint I posted on OSF. See also this short video.
Jul 9, 2021
Retrospective on a Fatal Dose-Finding Trial
tweetorials
This thread introduces an April 2020 paper I posted on arXiv, introducing a
therapeutic index
concept has become crucial to several later developments.
Jul 9, 2021
DIA IDSWG KOL Lecture
Many thanks to the DIA Innovative Designs Scientific Working Group (IDSWG — formerly ADSWG, A = Adaptive) for their kind invitation to give a KOL Lecture today. Special…
Sep 25, 2020
FDA OCE response on dose individualization
journal
Here is the text of FDA’s April 20, 2020 response to a query submitted on my behalf Jan 22 by the office of Congresswoman Rep. Pramila Jayapal. (Advance to page 2 of this…
Apr 21, 2020
Therapeutic Synergism and the Statistician
short-videos
This very short (2:20) video surveys the core argument of this working paper, which shows how 1-size-fits-all dosefinding ruins therapeutic synergism.
Jan 13, 2020
Comment on Wages et al., Coherence principles in interval-based dose finding
under-review
UPDATE: (Mar 30) Yesterday, PST published my letter online. Wages, Iasonos, O’Quigley & Conaway thus far appear to have offered no reply despite ample time to do so.
Dec 2, 2019
On the MTD heuristic and the TLA shell-game
*TLA = Three-Letter Acronym
Aug 9, 2019
Missed opportunities at Phase 1 Manchester
journal
“
Phase 1: Where Science Becomes Medicine
”
was the apt title of last week’s conference in Manchester England, devoted to phase 1 trials in oncology. The
‘Science’
and
‘Medicin…
Jul 25, 2019
‘Interventional pharmacoeconomics’ debases drugs and pharmacology alike
unfit_to_print
A Letter to the Editor of JAMA Oncology, desk-rejected July 15, 2019:
Jul 16, 2019
Precautionary Coherence for IRBs
short-videos
This very short (2:20) video introduces the Precautionary Coherence principle for IRB (Institutional Review Board) audiences. You can find a more detailed exposition of the…
Apr 25, 2019
Publications
This site is devoted to the lay outreach component of my research programme in
dose individualization
for cancer treatments. At the core of this research lies a…
Apr 25, 2019
Into the Mind of the
#OneSizeFitsAllogist
longer-videos
I have on my bookshelf a 300-page book devoted entirely to
1-size-fits-all dose finding
—a practice that any sensible layperson sees immediately as utterly wrongheaded. When…
Apr 17, 2019
DTAT for Pharma Investors
short-videos
Pharma investors’ tolerance for 1-size-fits-all dose finding continues to astonish me. In this short video, I put the case for making early-phase trial methodology an issue…
Apr 17, 2019
One-size-fits-all dosing of cancer treatment drugs: How much does it cost society?
explainers
This is a lay explainer for my bioRxiv preprint
Costing ‘the’ MTD
.
Apr 16, 2019
Clinicians must regain control over phase 1 cancer combination-therapy trials
explainers
This is a lay explainer for my bioRxiv preprint
Costing ‘the’ MTD … in 2-D
.
Apr 16, 2019
On the elementary nature of Precautionary Coherence
dialogues
The following hypothetical dialogue illustrates the
elementary
nature of the ‘precautionary coherence’ (PC) argument that I have detailed elsewhere. This dialogue occurs…
Apr 16, 2019
A new concept may help us at last abandon one-size-fits-all dosing of cancer treatment drugs
explainers
This is a lay explainer for my F1000Research paper,
Dose Titration Algorithm Tuning (DTAT) should supersede ‘the’ Maximum Tolerated Dose (MTD) in oncology dose-finding trials
.
Apr 16, 2019
Dose-finding realism that resonates with clinicians
unfit_to_print
A Letter to the Editor of Clinical Cancer Research, desk-rejected Oct 19, 2018:
Apr 15, 2019
Dose escalation belies the therapeutic intent of phase I trials
unfit_to_print
Adapted from the text of a ‘Comments and Controversies’ piece rejected by the Journal of Clinical Oncology in April 2018
Apr 14, 2019
The conduct of most first-in-human oncology drug trials is conceptually incoherent, and unethical.
explainers
This is a lay explainer for my bioRxiv preprint
Precautionary Coherence Unravels Dose Escalation Designs
.
Apr 14, 2019
No matching items